CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
UC Foundation celebrates 2026 philanthropy winners
October 23, 2026
The University of Cincinnati Foundation recognized its Outstanding Philanthropic Volunteer Award honorees at the George Rieveschl Recognition Dinner on October 22, 2026.
AI breast cancer survival model from Cancer Center could improve accuracy and personalize care
October 23, 2026
UC Cancer Center researchers, including lead author Wedad Alatebi, developed a deep learning survival model for breast cancer that combines detailed clinical and genetic information, potentially offering physicians a more accurate tool to guide treatment decisions.
UC expert explains potential impact of Pennsylvania’s new vape product law
October 22, 2026
UC professor Ashley Merianos speaks to the Pittsburgh Post-Gazette about Pennsylvania’s new vape law, youth vaping prevention, enforcement challenges and possible unintended consequences.